Axenya Series A Raises $12 Million to Scale Corporate Healthcare in Brazil

Summary Box of the Axenya Investment

Brazilian healthtech Axenya has raised $12 million in a Series A round led by Canary and Indicator Capital, with participation from Zentynel. The investment will accelerate Axenya’s AI-driven corporate healthcare platform, already delivering measurable cost reductions for employers.

The Deal

Axenya Series A funding closed at $12 million (~BRL 65 million), led by Canary and Indicator Capital, with additional participation from Zentynel.

Founded in 2020 by Mariano Garcia‑Valiño, Renato De Giorgi and Esteban Rubin, Axenya has positioned itself at the intersection of corporate healthcare and technology. Its model is built on two core platforms: LifeVault, a data hub that consolidates clinical, operational, and administrative records, and Axenya IQ, an AI-powered predictive engine that anticipates risks, guides interventions, and reduces costs for employers and insurers.

Business Strategy and Market Impact in Axenya Funding

Axenya Series A round ranks among the largest early-stage healthtech financings in Brazil. Investors praised the company’s ability to deliver tangible, cost-saving outcomes. Canary’s Kristian Huber highlighted measurable results for employers, while Indicator Capital’s Thomas Bittar underscored Axenya’s potential to redefine corporate health management through predictive intelligence and device integration.

Results reported by corporate clients include:

• Medical inflation up to 50% below the market average
• 22% reduction in overall healthcare costs year-on-year
• 40% drop in spending on high-risk patients
• 50% lower cost per consultation/procedure, even with 13% more usage

In 2023, Axenya acquired HealthAPI to strengthen its interoperability infrastructure. With this Series A, the startup will accelerate commercial expansion, roll out new predictive modules, and deepen integration with digital biomarkers, IoT monitoring, and digital therapeutics (DTx). Its target is to monitor 1 million lives via AI and sustain up to 45% healthcare cost reductions over the next five years.

The Firms Behind the Deal

Demarest Advogados acted as Brazilian legal counsel to Axenya.

The firm’s team was led by partners Juliana Maluf and Beatriz Seixas, supported by associates Ilson Maciel and Pedro Uchino.

Demarest Advogados has consistently positioned itself as a key player in advising both domestic and international investors in Brazil’s fast-growing healthtech sector.

Conclusion

The Axenya Series A highlights the growing strength of Brazil’s healthtech ecosystem. By combining AI, interoperability, and predictive insights, Axenya is positioning itself as a disruptive player in corporate healthcare at a moment when employers are seeking cost-control and measurable returns.

Related Reading to Axenya Series A

• DASA’s Strategic Moves in Healthcare
• Mevo Raises Funding to Scale Pharmacy-as-a-Service
• Beep Saúde Lands Investment of $15 million

See how Axenya’s raise fits into our broader Week Review Brazil Deals.

Resumo em português

A healthtech Axenya levantou US$12 milhões (~BRL 65 milhões)em rodada Série A liderada pela Canary e pela Indicator Capital, com participação da Zentynel. O Demarest Advogados atuou na operação, com as sócias Juliana Maluf e Beatriz Seixas e os associados Ilson Maciel e Pedro Uchino. A empresa busca monitorar 1 milhão de vidas por IA e reduzir custos de saúde em até 45% nos próximos cinco anos.